EvaluatePharma World Preview 2012
REQUEST YOUR FREE COPY OF WORLD PREVIEW 2012
The first edition of EvaluatePharma’s World Preview brings together many of our analyses to provide a top level insight into the expected performance of the industry between now and 2012.
Based on our coverage of the world’s leading pharmaceutical and biotech companies, the World Preview 2012 highlights trends in prescription drugs sales, patent risk, R&D spend, global brand sales and therapeutic performance. Included in the report is a brief review of 2007 performance.
Key findings include:
- Worldwide Prescription Drug Sales Total $753 billion in 2012: Growth slows to 4.6% (CAGR) over 2009-2012
- By 2012, the top 4 global pharma companies will all be based in Europe.
- Over $120bn of Sales at Risk from Patent Expirations in 2011/12
- Biotechnology Products to Represent 44% of the World’s Top 100 Product Sales by 2012
- Global Pharmaceutical R&D Spend to Grow by 5% (CAGR) to $148bn by 2012
- Vaccines Set to Record Highest Growth of Major Therapy Categories to 2012
- Sales Potential of 2007 New Drugs (NMEs) Down 37% vs. 2006 Cohort of NMEs
Read the full report:
REQUEST YOUR FREE COPY OF WORLD PREVIEW 2012
| 
